InsiderTrades

Form 4 for TYRA Tyra Biosciences, Inc.

Accepted 2024-02-08 00:00:00 ET · period of report 2024-02-06 · accession 0001415889-24-003043 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DI 2024-02-08 2024-02-06 TYRA Shah Rajeev M. Dir, 10% A - Grant $13.01 +3.18M 8.48M +60% +$41.37M
DI 2024-02-08 2024-02-06 TYRA Shah Rajeev M. Dir, 10% A - Grant $13.01 +1.54M 1.54M New +$20.02M

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-02-06 A A 3,180,155 $13.01 8,477,275 I See footnotes — — (F1) These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). (F2) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
2 Derivative Pre-Funded Warrants (Right to Buy) 2024-02-06 A A 1,538,457 $13.01 1,538,457 I See footnotes $0.00 · — to — 1,538,457 Common Stock (F1) These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). (F2) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. (F5) The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.